Quick Answer
Avalo Therapeutics, Inc. reported Operating Income of -$72.92 million for fiscal year 2025.
Avalo Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$72.92M | -6.4% |
| 2024 | -$68.51M | -150.5% |
| 2023 | -$27.35M | +26.9% |
| 2022 | -$37.44M | +54.4% |
| 2021 | -$82.13M | -12.8% |
| 2020 | -$72.84M | -351.4% |
| 2019 | -$16.14M | +54.4% |
| 2018 | -$35.38M | -354.7% |
| 2017 | $13.89M | +186.4% |
| 2016 | -$16.08M | -46.1% |
| 2015 | -$11.01M | +35.7% |
| 2014 | -$17.12M | -32.3% |
| 2013 | -$12.93M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$19.20M | -49.3% | +0.6% |
| June 30, 2025 | -$19.32M | -101.7% | -31.7% |
| March 31, 2025 | -$14.67M | +55.2% | -14.1% |
| September 30, 2024 | -$12.86M | -243.0% | -34.3% |
| June 30, 2024 | -$9.57M | -33.9% | +70.8% |
| March 31, 2024 | -$32.77M | -272.7% | -773.8% |
| September 30, 2023 | -$3.75M | -191.6% | +47.6% |
| June 30, 2023 | -$7.15M | +39.6% | +18.7% |
- Avalo Therapeutics, Inc. showed a decrease of -6.4% in Operating Income compared to the prior fiscal year.
- Over the 2013–2025 period, Avalo Therapeutics, Inc.’s operating income has declined by 463.8% (from -$12.93 million to -$72.92 million).
- The most recent figure is from Avalo Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: